Office of Commercialization and Economic Development
Office of Technology Commercialization

Methods And Compositions For CSPG4 Chimeric Antigen Receptor Targeting Cancer Cells

Technology #18-0087

Glioblastoma (GBM) is a lethal primary brain cancer, surgery, radiotherapy, and chemotherapy have little impact on survival.  CSPG4 is an attractive target for immunotherapy in GBM, it is highly expressed in GBM with limited intratumoral heterogeneity  little expression in the normal brain parenchyma. CSPG4 is expressed in considerable amounts not only in GBM  but also other tumors including melanoma, head and neck cancer, and triple negative breast cancer.